Notably, Teva and GILD did not settle re the Truvada patent, so GILD will have to adopt one of two approaches to fully protect Truvada from generic competition: a) relying on the Emtriva formulation patents in the Orange Book, which run beyond 2020; or b) developing TAF (f/k/a GS-7340) as a replacement for Viread and marketing a TAF + Emtriva combination pill to supersede Truvada.
Having patent coverage on Stribild and Complera (of which Truvada is a component) provides additional protection, so GILD’s HIV franchise in the US will still be in a good shape even if neither of the two approaches mentioned above for protecting standalone Truvada pans out.
News 
Market Data 
Discover 
